Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mayocpiqo.2020.09.010 http://scihub22266oqcxt.onion/10.1016/j.mayocpiqo.2020.09.010 33073177!7550090!33073177     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mayo+Clin+Proc+Innov+Qual+Outcomes 2020 ; 4 (6): 759-763 Nephropedia Template TP {{tp|p=33073177|t=2020. Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2 |pdf=|usr=}}{{33073177}} gab.com Text Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2 JO: Mayo Clin Proc Innov Qual Outcomes http://www.kidney.de/pget.php?&tw=1&pmid=33073177 #FOAvip In many different infectious syndromes, most notably several viral conditions, time to therapy initiation from symptom onset has been identified as a critical component contributing to the success of therapy. Regarding COVID-19, several therapeutic antivirals, both repurposed and novel, have been evaluated for overall safety and efficacy. As the literature related to these therapies has expanded recently, a wide array of trial designs, time to therapy initiation thresholds, and clinical outcomes in regard to time to initiation have been reported. We describe the potential effects of time to therapy initiation on outcomes in patients with COVID-19 and detail the existing data surrounding this topic in relation to remdesivir, convalescent plasma, lopinavir/ritonavir, and hydroxychloroquine. Twit Text FOAVip Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2 ????Mayo Clin Proc Innov Qual Outcomes http://www.kidney.de/pget.php?&tw=1&pmid=33073177 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33073177 #FOAvip English Wikipedia <ref>{{Cite pmid|33073177}}</ref> Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2 #MMPMID33073177 Stevens RW; Rivera CG; Saleh OA Mayo Clin Proc Innov Qual Outcomes 2020[Dec]; 4 (6): 759-763 PMID33073177show ga In many different infectious syndromes, most notably several viral conditions, time to therapy initiation from symptom onset has been identified as a critical component contributing to the success of therapy. Regarding COVID-19, several therapeutic antivirals, both repurposed and novel, have been evaluated for overall safety and efficacy. As the literature related to these therapies has expanded recently, a wide array of trial designs, time to therapy initiation thresholds, and clinical outcomes in regard to time to initiation have been reported. We describe the potential effects of time to therapy initiation on outcomes in patients with COVID-19 and detail the existing data surrounding this topic in relation to remdesivir, convalescent plasma, lopinavir/ritonavir, and hydroxychloroquine. äTime to Treat: Applying Lessons Learned from Other Viral Syndromes to (epmc).pdf DeepDyve Pubget Overpricing